How to toggle the data charts?
Click the labels on the Legend (e.g. Male, Female, inpatient cost, Cohort 2014 etc)
Key Takeaways
Incidence Cases (New Cases)
Prostate Cancer cases in Hong Kong are expected to continue rising by around 3% per year. By 2032, the projected number of annual incidence cases is expected to range between 2000 to 3500.
Incidence Rate
The overall incidence rate of Prostate Cancer in Hong Kong remain stable in the next decade, with an overall incidence of around 5 per 10,000 persons.
Notes
1. Incident cases are new cases in the population each year.
2. Incident cases from 2023 to 2032 were forecasted using ARIMA (Auto Regressive Integrated Moving Average) models, trained on historical data from 2003 to 2022.
3. Incidence rate was calculated by dividing the number of newly diagnosed cases (no previous diagnosis) for that year by the midyear male population estimate.
4. Age standardization was performed using the direct method, with the 2022 Hong Kong Population as the reference.
5. Incidence rates from 2023 to 2032 were forecasted using ARIMA models, trained on historical data from 2003 to 2022.
Average annual percentage change (AAPC) indicates the average yearly rate of increase or decrease in a value over a specified period.
Key Takeaways
Prevalence Cases (Existing Cases)
The number of males living with prostate cancer in Hong Kong is steadily rising and is expected to continue increasing by 4% per year over the next decade. The prevalence number is likely to exceed 25,000 in 2032.
Prevalence rate
The prevalence rate of Prostate Cancer among males in Hong Kong is rising by about 20% in the next decade. The overall prevalence rate is about 66 per 10,000 persons in 2032.
Notes
1. Prevalent cases are persons who were existing cases in the population each year.
2. Prevalent cases from 2023 to 2032 were forecasted using ARIMA (Auto Regressive Integrated Moving Average) models, trained on historical data from 2003 to 2022.
3. Prevalence rate was calculated by dividing the number of existing cases for that year by the midyear male population estimate.
4. Age standardization was performed using the direct method, with the 2022 Hong Kong Population as the reference.
5. Prevalence rates from 2023 to 2032 were forecasted using ARIMA models, trained on historical data from 2003 to 2022.
Average annual percentage change (AAPC) indicates the average yearly rate of increase or decrease in a value over a specified period.
Key Takeaways
The healthcare costs of prostate cancer in Hong Kong are projected to increase gradually until 2032 by around 3% per year. In 2032, it is projected that the cost of care for prostate cancer would exceed 1,000 million.
Notes
1. The cost refers to the all-cause cost for that calendar year, including all healthcare resource utilization expenses across all settings.
2. Unit costs are based on fees and charges for public hospital services set by the Hospital Authority, effective from 2017.
3. Cost projections (2023–2032) were forecasted using ARIMA (Auto Regressive Integrated Moving Average) models trained on 2003–2022 data, adjusted for the 2020–2022 pandemic.
Key Takeaways
Castration-Resistant Prostate Cancer (CRPC)
Over half the of patients with Castration-Resistant Prostate Cancer face a delay in receiving advanced care.
Notes
1. CRPC is defined as castrate-level serum testosterone (<50 ng/dL or 1.7 nmol/L) with either biochemical progression (three consecutive PSA rises with PSA >2 ng/mL) or radiological progression (new lesions on imaging).
2. Patients with unmet needs are defined as those who were not treated with novel hormonal agents or chemotherapy (including docetaxel, cabazitaxel, abiraterone, enzalutamide, apalutamide and duralutamide) after metastasis or progression of castration-resistance.
3. The 30- and 180-day grace periods were based on medical advice from clinical practice and expert opinions.
% Proportion of CRPC patients not treated by NHA/docetaxel in 180 Days in the yearly prostate cancer cohort
Key Takeaways
Metastatic Prostate Cacner
A larger proportion of patients with metastatic Prostate Cancer in Hong Kong are receiving timely advanced treatment in the past decade. In 2022, 67.2% of patients with metastatic prostate cancer still face delays in receiving care.
Notes:
1. Patients with unmet needs are defined as those who were not treated with novel hormonal agents or chemotherapy (including docetaxel, cabazitaxel, abiraterone, enzalutamide, apalutamide and duralutamide) after metastasis or progression of castration-resistance.
2. The 30- and 180-day grace periods were based on medical advice from clinical practice and expert opinions.
% Proportion of metastatic patients not treated by NHA/docetaxel in 180 Days in the yearly prostate cancer cohort
Abbreviations: CRPC: Castration-Resistant Prostate Cancer; NHA: Novel hormonal agents.
Key Takeaways
There is higher Survival Probability (life expectancy) in younger patients with prostate cancer. Overall, around 50% of prostate cancer patients have a life expectancy of nine years. The life expectancy declines with increasing age at diagnosis. The median life expectancy is less than three years for patients aged above 80.
